Igenica Biotherapeutics, a Burlingame, Calif., U.S. biotechnology company with a promising anti-cancer antibody in a Phase 1 clinical trial, has innovative technology platforms to discover and develop antibody drug conjugates (ADCs) for cancer treatment.
To fulfill the company’s goal of quickly moving an ADC-based therapeutics out of preclinical development and into the clinic, Igenica wanted new dedicated, industry-standard instrumentation to fully analyze the complexity and variation within an ADC’s three parts: the antibody, the toxic drug, and the linker that binds them together.
As a result, Igenica deployed Waters Biopharmaceutical Platform Solution with UNIFI, which includes the ACQUITY UPLC H-Class System, Xevo G2-S QTof Mass Spectrometer, and UNIFI Scientific Information System.
“The Waters Biopharmaceutical Platform has provided a superior window of insight into the molecules we are making,” said Mark R. Flory, Ph.D., a principal scientist at Igenica. “It will help in our efforts to accelerate clinical trials with ADCs.”